Wells Fargo & Company Aldeyra Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 395,297 shares of ALDX stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
395,297
Previous 387,304
2.06%
Holding current value
$2.05 Million
Previous $1.27 Million
3.32%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ALDX
# of Institutions
108Shares Held
35.3MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$48 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$28.4 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$19.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.8 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$8.29 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $302M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...